Mabion SA
🇵🇱Poland
- Country
- 🇵🇱Poland
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.mabion.eu
Clinical Trials
4
Active:1
Completed:2
Trial Phases
2 Phases
Phase 1:1
Phase 3:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 3
3 (75.0%)Phase 1
1 (25.0%)MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis
Phase 3
Withdrawn
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Mabion SA
- Registration Number
- NCT04680962
MabionCD20 Compared to MabThera in Lymphoma Patients
Phase 3
Completed
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Mabion SA
- Target Recruit Count
- 143
- Registration Number
- NCT02617485
- Locations
- 🇧🇦
University Clinical Center Banja Luka, Banja Luka, Bosnia and Herzegovina
🇧🇦University Clinical Center Sarajevo, Sarajevo, Bosnia and Herzegovina
🇧🇦University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina
MabionCD20® Compared to MabThera® in Patients With Rheumatoid Arthritis
- First Posted Date
- 2015-06-11
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Mabion SA
- Target Recruit Count
- 709
- Registration Number
- NCT02468791
- Locations
- 🇧🇦
Clinical Centre Banja Luka Location Paprikovac, Banja Luka, Bosnia and Herzegovina
🇧🇦University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina
🇧🇦Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina
News
No news found